• 1
    Sanger GJ. 5-Hydroxytryptamine and functional bowel disorders. Neurogastroenterol Motil 1996; 8: 31931.
  • 2
    Spiller RC. Effects of serotonin on intestinal secretion and motility. Curr Opin Gastroenterol 2001; 17: 99103.
  • 3
    Tack J, Sarnelli G. Serotonergic modulation of visceral sensation: upper gastrointestinal tract. Gut 2002; 51(Suppl. 1): i7780.
  • 4
    Bearcroft CP, Perrett D, Farthing MJG. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998; 42: 426.
  • 5
    Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52: 66370.
  • 6
    Lea R, Houghton LA, Whorwell PJ, Whitaker RP. Evidence for increased plasma 5-hydroxytryptamine (5-HT) concentration following meal ingestion in patients with functional dyspepsia (FD) and its relationship to gender and symptoms. Gastroenterology 2002; 122(4): 304.
  • 7
    Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 165566.
  • 8
    Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 6716.
  • 9
    Coffin B, Farmachidi JP, Ruegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 57785.
  • 10
    Degen L, Matzinger D, Mertz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 174551.
  • 11
    Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation predominant irritable bowel syndrome. Gastroenterology 2000; 118: 4638.
  • 12
    Tack J, Ligozio DG, Sue S, Lefkowitz M, Vandeplassche L. A phase II placebo controlled randomised trial with tegaserod (T) in functional dyspepsia (FD) patients with normal gastric emptying (NGE). Gastroenterology 2002; 122(4): 154.
  • 13
    Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 114959.
  • 14
    Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 84955.
  • 15
    Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhoea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 26716.
    Direct Link:
  • 16
    Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in both patients with irritable bowel syndrome, and healthy volunteers. Aliment Pharmacol Ther 2000; 14: 86978.
  • 17
    Talley NJ, Van Zanten SV, Saez LR, et al. A dose-ranging, placebo-controlled, randomised trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 52537.
  • 18
    Kuo B, Camilleri M, Burton D, et al. Effects of 5-HT3 antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther 2002; 16: 22533.
  • 19
    Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 134652.
  • 20
    Houghton LA, Fowler P, Keene ON, Read NW. Effect of sumatriptan, a new selective 5-HT1-like agonist, on liquid emptying in man. Aliment Pharmacol Ther 1992; 6: 68591.
  • 21
    Coulie B, Tack J, Maes B, Geypens B, DeRoo M, Janssens J. Sumatriptan, a selective 5-HT1-receptor agonist, induces a lag phase for the emptying of liquids in humans. Am J Physiol 1997; 272: G9028.
  • 22
    Coulie B, Tack J, Sifrim D, Andrioli A, Janssens J. Role of nitric oxide in fasting gastric fundus tone and in 5-HT1 receptor-mediated relaxation of gastric fundus. Am J Physiol 1999; 276: G3737.
  • 23
    Read NW, Houghton LA. Physiology of gastric emptying and pathophysiology of gastroparesis. In: OuyangA, ed. Gastroenterology Clinics of North America, 18(No. 2). Philadelphia: W.B. Saunders, 1989: 35974.
  • 24
    Boeckxstaens GE, Hirsch DP, Kuiken SD, Heisterkamp SH, Tytgat GNJ. The proximal stomach and postprandial symptoms in functional dyspeptics. Am J Gastroenterol 2002; 97: 408.
    Direct Link:
  • 25
    Tack J, Coulie B, Wilmer A, Peeters T, Janssens J. Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptan on interdigestive gastrointestinal motility in man. Gut 1998; 42: 3641.
  • 26
    Houghton LA, Read NW, Heddle R, et al. Motor activity of the gastric antrum, pylorus and duodenum under fasted conditions and after a liquid meal. Gastroenterology 1988; 94: 127684.
  • 27
    Houghton LA, Read NW, Heddle R, et al. Relationship of the motor activity of the antrum, pylorus and duodenum to gastric emptying of a solid–liquid mixed meal. Gastroenterology 1988; 94: 128591.
  • 28
    Kwong NK, Brown BH, Whittaker G, Duthie HL. Electrical activity, motility and acid secretion of the human stomach. Br J Surg 1970; 57: 384.
  • 29
    Duthie HJ, Brown BH, Robertson-Dunn B, Kwong NK, Whittaker GE, Waterfall W. Electrical activity in the gastroduodenal area — slow waves in the proximal duodenum: a comparison of man and dog. Am J Dig Dis 1972; 17: 34451.
  • 30
    Heddle R, Fone D, Dent J, Horowitz M. Stimulation of pyloric motility by intraduodenal dextrose in normal subjects. Gut 1988; 29: 134957.
  • 31
    Houghton LA, Kerrigan DD, Read NW. Effect of intragastric infusion of acid on the antropyloroduodenal motor unit in human volunteers. J Gastrointest Motil 1990; 2(3): 2028.
  • 32
    Heddle R, Dent J, Read NW, et al. Antropyloroduodenal motor responses to intraduodenal lipid infusion in healthy volunteers. Am J Physiol 1988; 254: G6719.
  • 33
    Fone DR, Horowitz M, Maddox A, Akkermans LM, Read NW, Dent J. Gastroduodenal motility during the delayed gastric emptying induced by cold stress. Gastroenterology 1990; 98: 115561.
  • 34
    Peeters TL, Janssens J, Vantrappen G. Somatostatin and the interdigestive migrating motor complex in man. Regul Pept 1983; 5: 20917.
  • 35
    Tack J, Janssens J, Vantrappen G, et al. Dose-related effect of erythromycin on gastroduodenal motility and plasma motilin levels. Studies in healthy volunteers and in patients with diabetic gastroparesis. Gastroenterology 1991; 103: 729.
  • 36
    Stanghellini V, Malagelada J-R, Zinsmeister AR, Go VLW, Kao PC. Stress-induced gastrointestinal motor disturbances in humans: possible humoral mechanisms. Gastroenterology 1983; 85: 8391.
  • 37
    Jones K, Edelbroek M, Horowitz M, et al. Evaluation of antral motility in humans using manometry and scintigraphy. Gut 1995; 37: 6438.
  • 38
    Camilleri M, Malagelada J-R, Brown ML, Becker G, Zinsmeister AR. Relation between antral motility and gastric emptying of solids and liquids in humans. Am J Physiol 1985; 249: G5805.
  • 39
    Jacobs F, Akkermanns LMA, Oei HY, Hoekstra A, Wittebol P. A radioisotope method to quantify the function of fundus, antrum, and their contractile activity in gastric emptying of a semi-solid and solid meal. In: WeinbeckM, ed. Motility of the Digestive Tract. New York: Raven Press, 1982: 23340.
  • 40
    Tougas G, Anvari M, Dent J, Somers S, Richards D, Stevenson GW. Relationship of pyloric motility to pyloric opening and closure in healthy subjects. Gut 1992; 33: 46671.
  • 41
    Heddle R, Collins P, Dent J, et al. Motor mechanisms associated with slowing of the gastric emptying of a solid meal by an intraduodenal lipid infusion. J Gastroenterol Hepatol 1989; 4: 43744.
  • 42
    Anvari M, Malbert C-H, Dent J, Jamieson GG. Mechanics of pulsatile transpyloric flow in the pig. J Physiol (Lond) 1995; 488: 193202.
  • 43
    Horowitz M, Dent J, Fraser R, Sun WM, Hebbard G. Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci 1994; 39(Suppl. 12): 7S13S.
  • 44
    Malbert C-H, Mathis C. Antropyloric modulation of transpyloric flow of liquids in pigs. Gastroenterology 1994; 107: 3746.
  • 45
    Sun WM, Doran S, Jones KL, et al. Effects of nitroglycerin on liquid gastric emptying and antropyloroduodenal motility. Am J Physiol 1998; 275: G11738.
  • 46
    Beattie DT, Connor HE, Feniuk W, et al. The pharmacology of sumatriptan. Rev Contemp Pharmacother 1994; 5: 28594.
  • 47
    Tack J. Receptors of the enteric nervous system: potential targets for drug therapy. Gut 2000; 47(Suppl. IV:): iv20.
  • 48
    Sleight AJ, Cervenka A, Peroutka SJ. In vivo effects of sumatriptan (GR43175) on extracellular levels of 5-HT in the guinea-pig. Neuropharmacology 1990; 29: 5113.
  • 49
    Dechant KL, Clissold SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992; 43: 77698.
  • 50
    Russo A, Fraser R, Adachi K, Horowitz M, Boeckxstaens G. Evidence that nitric oxide mechanisms regulate small intestinal motility in humans. Gut 1999; 44: 726.
  • 51
    Sun WM, Doran S, Lingerfelser TH, et al. Effects of glyceryl trinitrate on the pyloric motor response to intraduodenal triglyceride infusions in humans. Eur J Clin Invest 1996; 26: 65764.
  • 52
    De Ponti F, Crema F, Moro E, Nardelli G, Frigo G, Crema A. Role of 5-HT1B/D receptors in canine gastric accommodation: effect of sumatriptan and 5-HT1B/D receptor antagonists. Am J Physiol 2003; 285: G96104.
  • 53
    Kaumann AJ, Parsons AA, Brown AM. Human arterial constrictor serotonin receptors. Cardiovasc Res 1993; 27: 2094103.
  • 54
    Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet 1994; 344: 9856.
  • 55
    Foster JM, Houghton LA, Whorwell PJ, Morris J. Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan. Aliment Pharmacol Ther 1999; 13: 92736.
  • 56
    Sifrim D, Holloway RH, Tack J, et al. Effect of sumatriptan, a 5-HT1 agonist, on the frequency of transient lower esophageal sphincter relaxations and gastroesophageal reflux in healthy subjects. Am J Gastroenterol 1999; 94: 315864.
    Direct Link:
  • 57
    Foster JM, Houghton LA, Whorwell PJ. Sumatriptan, a 5-HT1 agonist, increases gastroesophageal reflux. Gut 1998; 42: A64(Abstract).
  • 58
    Foster JM, Houghton LA, Whorwell PJ. Further evidence that sumatriptan induced chest pain is oesophageal in origin: effect of oesophageal visceral sensation. Gastroenterology 1997; 112: A733(Abstract).
  • 59
    Chester AH, O'Neil GS, Yaccoub MH. Sumatriptan and ischaemic heart disease. Lancet 1993; 341: 141920.